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A EROSOLIZED administration of antibiotics to treat respiratory infections in critically ill patients was described 
more than 40 yr ago.1 Supported by experimental studies,2,3 
several clinical studies demonstrated that the endotracheal 
administration of polymyxin B or gentamicin prevented ventila-
tor-associated pneumonia (VAP).4–7 However, when it was pro-
phylactically administered beyond 1 week, the incidence of VAP 
caused by polymyxin B- resistant pathogens increased,8 leading 
the critical care community to abandon this administration 
method. During the 1990s, an enhanced understanding of con-
ditions required for reaching the deep lung during mechanical 
ventilation,9 together with the development of new-generation 
nebulizers,10–13 contributed to its reemergence. In 1998, a 
study performed in tracheostomized patients suggested that the 
What We Already Know about This Topic
• In critically ill patients, nebulized antibiotics are increasingly 
used; however, the safety and efficacy of these are unknown
What This Article Tells Us That Is New
• A systematic review reports that the data are sparse; however, 
nebulization may be more effective in cases of resistant 
organisms and less nephrotoxic (if replacing nephrotoxic 
systemic agents) but may compromise mechanical ventilation 
especially in hypoxemic patients
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ABSTRACT
Background: Nebulization of antiinfective agents is a common but unstandardized practice in critically ill patients.
Methods: A systematic review of 1,435 studies was performed in adults receiving invasive mechanical ventilation. Two differ-
ent administration strategies (adjunctive and substitute) were considered clinically relevant. Inclusion was restricted to studies 
using jet, ultrasonic, and vibrating-mesh nebulizers. Studies involving children, colonized-but-not-infected adults, and cystic 
fibrosis patients were excluded.
Results: Five of the 11 studies included had a small sample size (fewer than 50 patients), and only 6 were randomized. Diversity 
of case-mix, dosage, and devices are sources of bias. Only a few patients had severe hypoxemia. Aminoglycosides and colistin 
were the most common antibiotics, being safe regarding nephrotoxicity and neurotoxicity, but increased respiratory complica-
tions in 9% (95% CI, 0.01 to 0.18; I2 = 52%), particularly when administered to hypoxemic patients. For tracheobronchitis, a 
significant decrease in emergence of resistance was evidenced (risk ratio, 0.18; 95% CI, 0.05 to 0.64; I2 = 0%). Similar findings 
were observed in pneumonia by susceptible pathogens, without improvement in mortality or ventilation duration. In pneumo-
nia caused by resistant pathogens, higher clinical resolution (odds ratio, 1.96; 95% CI, 1.30 to 2.96; I2 = 0%) was evidenced. 
These findings were not consistently evidenced in the assessment of efficacy against pneumonia caused by susceptible pathogens.
Conclusions: Performance of randomized trials evaluating the impact of nebulized antibiotics with more homogeneous popu-
lations, standardized drug delivery, predetermined clinical efficacy, and safety outcomes is urgently required. Infections by 
resistant pathogens might potentially have higher benefit from nebulized antiinfective agents. Nebulization, without concomi-
tant systemic administration of the drug, may reduce nephrotoxicity but may also be associated with higher risk of respiratory 
complications. (Anesthesiology 2017; 126:890-908)
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nebulization of aminoglycosides using a jet nebulizer, producing 
appropriate mass median aerodynamic diameter aerosol particles, 
was appropriate for treating ventilator-associated tracheobron-
chitis (VAT).14 Between 2000 and 2010, experimental studies 
on pharmacokinetics/pharmacodynamics using ultrasonic or 
vibrating-mesh nebulizers in mechanically ventilated piglets15–18 
increased the understanding of several factors influencing nebu-
lization performance, which renewed the interest for antibiotic 
nebulization.19–23 Respiratory infections have also become more 
difficult to treat due to greater levels of host immunosuppression 
and an increasing prevalence of drug-resistant pathogens.24,25 
These factors make daily clinical practice highly challenging, 
with intensivists considering alternative treatment strategies, 
including nebulization. However, aerosol administration might 
lead to a potential increased risk of severe adverse events, such as 
cardiorespiratory or nephrotoxicity.23,26 Given this background, 
our main aim was to determine the efficacy and safety of this 
widely extended but yet unstandardized practice by performing 
a systematic review and meta- analysis of the existing literature. 
Recent reports describe the complexity and variability of admin-
istration practices,27 evidencing the differences in management 
for VAT and VAP. Our hypothesis was that nebulized antibiotics 
are safe and effective for therapy of nosocomial respiratory infec-
tions in invasively mechanical ventilation adults.
Materials and Methods
This report describes the results of the systematic review and 
meta-analyses under the guidance of the Preferred Reporting 
Items for Systematic Reviews and Meta-analyses (PRISMA) 
statement.28 A list of clinical questions under the PICO frame-
work (Population-Intervention-Comparison-Outcome) format 
was created (table 1). The selected population was adult critically 
ill patients, receiving support with invasive mechanical ventila-
tion, defined as ventilatory support through a nasotracheal tube, 
orotracheal tube, or tracheostomy. Noninvasive mechanical ven-
tilation or other respiratory support devices such as high-flow 
nasal therapy were not considered in our study. The respiratory 
infections considered were VAT, VAP, or severe hospital-acquired 
pneumonia. Patients who were colonized, with colonization 
defined as the presence of purulent tracheal secretions without 
infectious signs and radiologic infiltrate, were excluded from our 
analyses. The susceptibility pattern of the pathogens was simpli-
fied as susceptible or resistant, the latter including bacteria with 
any type of resistance criteria ( multidrug-, extensively drug-, or 
pandrug-resistant bacteria) defined by the Centers for Disease 
Control and Prevention (Atlanta, Georgia).29 Nebulization of 
the antibiotic had to be performed with any device generating 
particles sufficiently small to reach the lung parenchyma (jet, 
ultrasonic, or vibrating-mesh nebulizers).
Two different strategies for the administration of nebu-
lized antibiotics were considered clinically relevant for the 
treatment of VAP:
1. Adjunctive strategy: nebulized colistin or aminoglyco-
sides administered to patients already receiving IV colis-
tin or aminoglycosides, added to standard first-line IV 
antibiotics (in comparison to patients also receiving the 
same IV therapy, but no nebulized antibiotics).
2. Substitution strategy: nebulized colistin or aminoglycosides 
administered to patients not receiving IV colistin or aminogly-
cosides, but only standard first-line IV antibiotics (in compari-
son to patients receiving IV colistin or  aminoglycosides—not 
nebulized—added to the first-line IV antibiotics).
In agreement with the current trends of personalized medi-
cine,30 we postulated that similar interventions (nebulization of 
antibiotics) might have divergent effects in different subsets, jus-
tifying the formulation of multiple PICO questions with prede-
termined outcomes. Therefore, the evaluated safety and efficacy 
predefined outcomes (table 2) were determined as enclosed: (1) 
adverse events (nephrotoxicity, neurotoxicity and cardiorespira-
tory complications); (2) emergence of resistance and superin-
fection; (3) clinical resolution and mortality; and (4) length of 
intensive care unit stay and mechanical ventilation.
Efficacy outcomes were evaluated according to both the 
susceptibility pattern of the pathogen and the administration’s 
strategy. None of the safety outcomes was considered to be pos-
sibly influenced by the susceptibility pattern of the pathogen; 
therefore, this factor was not taken into consideration in their 
analysis. Evaluation of systemic toxicity was performed accord-
ing to the administration strategy for better discrimination of 
their impact. Occurrence of cardiorespiratory complications 
was considered not to be influenced by the specified adminis-
tration strategies, therefore this factor was not taken into con-
sideration in its analysis. The effect of nebulized antiinfective 
agents against viral and fungal infections was also assessed.
Information Sources
A global search strategy was systematically performed in 
three different databases: MEDLINE database through the 
PubMed search engine, EMBASE, and the Cochrane Library 
Database. Search terms are detailed in appendix 1. No restric-
tions of study design, time, or language were imposed. The 
first search was performed in June 2014, and it was repeated 
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in March 2015 and July 2016. No other eligible studies were 
identified by evaluating previous reviews, abstracts from 
meetings or under suggestion of the panel of experts.
Statistical Analysis
The eligibility criteria, study selection, data collection, and 
risk of bias assessment are described in detail in the appen-
dix 2. The main characteristics and quality of the studies are 
summarized in detail in appendix 3. Analysis of all outcomes 
was performed according to the design of the study, being 
either randomized controlled trials (RCTs) or observational 
studies, and their results are also presented accordingly. As 
the majority of the included studies had a small sample size, 
a pooled evaluation of all studies was also performed for each 
outcome, in order to detect a potential presence of clinically 
significant trends. This approach was considered acceptable 
due to the lack of large-scale data.
All statistical analyses were performed using Review 
Manager (RevMan) version 5.3. (Nordic Cochrane Centre, 
Cochrane Collaboration, Denmark, 2014). The summary 
statistic measures used for the evaluation of binary outcomes 
were the risk ratio for RCTs and the odds ratio (OR) for the 
observational study and pooled evaluation. Risk difference 
was also used where necessary. The summary statistic measure 
used for the evaluation of continuous outcomes was the mean 
difference. All statistical measures were calculated with 95% 
CI. Random-effects meta-analysis using the Mantel–Haenszel 
model approach was chosen to obtain pooled study results. The 
Higgins I2 test was predefined to quantify heterogeneity (I2 ≤ 
25% for low, 25% < I2 < 50% for moderate, and I2 ≥ 50% for 
high). Metaregression was not performed given the low num-
ber of studies included in the analysis. Assessment of publica-
tion bias using a funnel plot31,32 was planned when considered 
meaningful (i.e., at least 10 studies available).
Results
Study Selection
A total of 1,435 studies were identified: 898 studies in the 
MEDLINE database (PubMed), 327 in EMBASE, and 210 
in the Cochrane Library Database. After assessment for inclu-
sion, manually adjusting for duplicates, and revision of the 
articles, 11 studies were finally included in the meta-analysis. 
The PRISMA flow diagram33 of the studies’ selection is pre-
sented in figure 1.
No RCTs or observational studies were found to evalu-
ate the efficacy and/or safety of nebulized antivirals or anti-
fungals for the treatment of respiratory viral and fungal 
Table 1. Population-Intervention-Comparison-Outcome Framework
Population Intervention Comparator Outcome
Bacterial respiratory infections
  Regarding VAT
   MV patients with VAT Addition of nebulized antibiotics to their 
conventional IV antibiotic therapy




   MV patients with VAT Treatment with nebulized antibiotics 
(alone, no IV therapy)




  Regarding HAP or VAP
   Resistant pathogens
    MV patients with VAP 
caused by resistant 
pathogens
Adjunctive strategy: addition of nebulized 
colistin or aminoglycosides to IV colis-
tin or aminoglycosides plus standard 
first-line IV antibiotics
IV colistin or aminoglycosides 




    MV patients with VAP 
caused by resistant 
pathogens
Substitution strategy: nebulized colistin 
or aminoglycosides plus standard first-
line IV antibiotics
IV colistin or aminoglycosides 




   Susceptible pathogens
    MV patients with VAP 
caused by susceptible 
pathogens
Adjunctive strategy: addition of nebu-
lized colistin or aminoglycosides to 
IV  colistin or aminoglycosides plus 
standard first-line IV antibiotics
IV colistin or aminoglycosides 




    MV patients with VAP 
caused by susceptible 
pathogens
Substitution strategy: nebulized colistin 
or aminoglycosides plus standard 
 first-line IV antibiotics
IV colistin or aminoglycosides 





  MV patients with viral  
respiratory infection
Nebulized antivirals Conventional antiviral therapy Improvement of 
clinical outcome*
Fungal respiratory infections
  MV patients with fungal  
respiratory infection (including 
Pneumocystis jirovecii)




* Defined by the efficacy outcomes (table 2).
HAP = hospital-acquired pneumonia; IV = intravenous; MV = mechanically ventilated; VAP = ventilator-associated pneumonia; VAT = ventilator-associated 
tracheobronchitis.
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infections in mechanically ventilated patients. Characteris-
tics and results on efficacy and safety of their use are detailed 
in appendixes A4 and A5.
Six RCTs and five observational studies assessed the efficacy 
and safety of nebulized antibiotics for the treatment of bacterial 
infections, involving 826 patients. Five of the studies had a small 
sample size (fewer than 50 patients). The largest study was an 
observational study involving 208 patients. Five studies admin-
istered aminoglycosides, four administered colistin, and two 
administered both. Four studies used jet nebulizers, three studies 
used vibrating-mesh nebulizers, and three studies used different 
devices indistinctively (jet and ultrasonic nebulizers were used in 
two studies; the other study used jet and vibrating-mesh nebuliz-
ers). One of the studies did not detail the type of nebulizer used, 
but they did specify having used a device generating optimal-size 
droplets with diameter between 1 and 5 μm. The risk of bias of 
the included studies was globally low. The main characteristics 
of the included studies and the administration strategy to which 
they belong are described in table 3. A summary of their risk of 
bias of the included RCT is detailed in figure 2.
Treatment of VAT. Only two RCT by Palmer et al.34 and Palmer 
and Smaldone35 involving 85 patients evaluated the efficacy 
and safety of nebulized antibiotics. Both studies assessed 
efficacy, but neither of them did so in our predefined terms 
(both considered reduction of the Clinical Pulmonary Infec-
tion Score as a sign of clinical resolution). Meta-analysis of 
the results showed a greater reduction of the Clinical Pulmo-
nary Infection Score, with a high heterogeneity (mean differ-
ence, −3.11 points; 95% CI from −6.18 to −0.04; I2 = 90%), 
and significantly less emergence of resistant strains in patients 
receiving nebulized antibiotics (70 patients; risk ratio = 0.18; 
95% CI, 0.05 to 0.64; I2 = 0%). The forest plot is shown 
in figure 3. No significant differences were found in mortal-
ity and duration of mechanical ventilation. No significant 
difference in systemic toxicity (nephrotoxicity, indirectly mea-
sured by serum creatinine concentration) was found.
Efficacy of Nebulized Antibiotics for the Treatment of VAP 
Caused by Resistant Pathogens. Six studies were included 
in the analysis of the efficacy of nebulized antibiotics for the 
treatment of VAP caused by resistant pathogens.
Adjunctive Administration Strategy. Four studies administered 
nebulized antibiotics under this strategy; one RCT, Niederman 
et al.36 (administering nebulized amikacin in patients who could 
already be receiving IV aminoglycosides), and three observa-
tional studies: Kofteridis et al.,37 Doshi et al.,38 and Tumbarello 
et al.39 Efficacy was assessed by all of the included studies.
No significant difference in clinical resolution was evi-
denced in the RCT (48 patients; OR, 1.30; 95% CI, 0.22 
to 7.55), but it was significantly higher in patients receiv-
ing nebulized antibiotics in the meta-analysis of the obser-
vational study included (389 patients; OR, 0.51; 95% CI, 
0.34 to 0.77; I2 = 0%). Pooled meta-analysis of all studies 
(437 patients) also showed significantly better clinical reso-
lution rates in patients receiving nebulized antibiotics (OR, 
0.53; 95% CI, 0.36 to 0.80; I2 = 0%). The forest plot, strati-
fied according to the study design, is shown in figure 4.
Two observational studies37,38 reported VAP-related mor-
tality, which was found to decrease in patients receiving 
nebulized antibiotics (181 patients; OR, 0.5; 95% CI, 0.26 
to 0.96; I2 = 0%). All-cause mortality was reported by two 
observational studies37,39 with no difference in the mortality 
rates (294 patients; OR, 0.68; 95% CI, 0.33 to 1.37; I2 = 
46%), with moderate heterogeneity. The forest plot for mor-
tality is shown in figure 5.
A significant decrease in the length of mechanical venti-
lation support to patients receiving nebulized antibiotics was 
also evidenced (303 patients; 3.72 days fewer; 95% CI from 
−5.86 to −1.59 days; I2 = 0%) in the meta-analysis of the two 
observational studies that assessed it.38,39 The forest plot is 
shown in figure 6. No other significant differences were found 
in the rest of the efficacy outcomes assessed (duration of inten-
sive care unit stay and development of superinfection).
Substitution Administration Strategy. One observational 
study administered nebulized antibiotics under this strat-
egy: Ghannam et al.,40 involving 32 patients. Higher rates of 
clinical resolution in patients receiving nebulized antibiotics 
were reported (OR, 9.53; 95% CI, 1.85 to 49.2). Duration 
of mechanical ventilation and intensive care unit stay were 
similar, independently of the use of nebulized agents.
Efficacy of Nebulized Antibiotics for the Treatment of VAP 
Caused by Susceptible Pathogens. One RCT, Lu et al.,26 
was analyzed. In this trial, both aminoglycosides and ceftazi-
dime were administered either by nebulization or IV, with 
no other IV antibiotics being administered concomitantly, 
which was considered to be equivalent to the substitution 
administration strategy.
No significant differences were apparent for clinical 
resolution, mortality, duration of mechanical ventilation 
(median of 11 more days; P = 0.13), intensive care unit 
Table 2. Predefined Evaluated Outcomes
Efficacy outcomes
  Clinical resolution (yes/no; after 8 days of treatment) if one or 
more of the following occurred:
   Removal of vital support (ventilation, vasopressors)
   Improvement of daily organ failure score
          Improvement of PaO2/FIO2 ratio
          Inflammatory parameters decrease (C-reactive  
protein and/or procalcitonin)
  30-day mortality (yes/no)
  Duration of MV, days
  Duration of ICU stay, days
  Occurrence of superinfection (yes/no)
  Emergence of resistant strains (yes/no)
Safety outcomes
 Systemic toxicity (yes/no; especially nephrotoxicity)
Cardiorespiratory complications (yes/no; including hypoxemia; 
cough, bronchoconstriction, lung injury or acute respiratory 
distress syndrome; problems with the nebulization system 
such as obstruction of the expiratory filter; arrhythmias,  
cardiorespiratory arrest)
FIO2 = fraction of inspired oxygen; ICU = intensive care unit; MV = mechani-
cally ventilated; PaO2 = arterial oxygen partial pressure.
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stay (median of 9 more days; P = 0.08), and development 
of superinfection between the patients receiving nebulized 
antibiotics and the patients receiving systemic therapy. 
However, per-treatment emergence of resistant strains 
was considered to be potentially prevented by antibiotics 
nebulization, as new growth or persistence of infection was 
caused exclusively by susceptible strains in patients treated 
with nebulized antibiotics, while 50% of the strains became 
intermediate or resistant in the group of patients treated 
systemically.
Safety of Nebulized Antibiotics for the Treatment of VAP. 
Three additional studies were included in the meta-analysis 
for safety: two RCT, Hallal et al.41 and Rattanaumpawan et 
al.,42 and one observational study, Arnold et al.43
Evaluation of Systemic Toxicity of Nebulized Antibiot-
ics Administered according to the Adjunctive Strategy. 
Two types of systemic toxicity were reported: nephrotoxic-
ity36,37,39,42,43 and neurotoxicity.37,42 No significant difference 
was evidenced in the occurrence of nephrotoxicity (fig. 7A) or 
neurotoxicity between patients receiving nebulized antibiot-
ics and patients without intratracheal therapy.
Evaluation of Systemic Toxicity of Nebulized Antibiotics 
Administered according to the Substitution Strategy. Two 
studies reported nephrotoxicity events.40,41 The RCT40 did 
not show any difference in the risk of nephrotoxicity (risk 
difference, −0.40; 95% CI, −0.85 to 0.05), but the analysis 
of the observational study41 did show less occurrence of 
nephrotoxicity when nebulized antibiotics were adminis-
tered (risk difference, −0.31; 95% CI, −0.55 to −0.08). 
The pooled analysis of both (involving 42 patients) also 
showed significantly less occurrence of nephrotoxicity in 
patients receiving treatment with nebulized antibiotics 
(risk difference, −0.33; 95% CI, −0.54 to −0.12; I2 = 0%; 
fig. 7B).
All studies reporting data on cardiorespiratory com-
plications were analyzed together, according to the study 
design, but independently of the administration strat-
egy. The meta-analysis of two observational studies37,43 
showed no differences in the occurrence of cardiorespi-
ratory adverse events, with no heterogeneity (risk dif-
ference, 0.00; 95% CI from −0.04 to 0.04; I2 = 0%). 
Meta-analysis of the four RCTs included26,36,41,42 showed 
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) flow diagram of the study selection. 
*Articles with one or more of the exclusion criteria detailed in appendix 2. NA = nebulized antibiotics.
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a 9% increase in incidence of respiratory complications 
in patients receiving nebulized antibiotics (risk differ-
ence, 0.09; 95% CI from −0.01 to 0.18; I2 = 52%), but 
high heterogeneity between studies was observed (fig. 
8). The combined analysis of all studies was similar but 
with higher heterogeneity (risk difference, 0.04; 95% CI, 
from −0.02 to 0.11; I2 = 75%). The study that registered 
more cardiorespiratory complications26 detailed that no 
bronchospasms were evidenced. Three patients with an 
initial severe hypoxemia (PaO2/FIO2 ratio of less than 200) 
suffered a 25% decrease in their PaO2 after the nebuliza-
tion. Three other complications were related to obstruc-
tion of the expiratory filter, detected in two of the cases 
by an increase in the peak airway pressure. The other 
patient suffered a secondary cardiac arrest. Finally, one 
patient had to be excluded in an early phase of the study 
due to severe hypoxemia secondary to alveolar derecruit-
ment induced by the nebulization.
discussion
Our study provides new information on the efficacy and 
safety of antibiotic nebulization in mechanically ventilated 
patients. This is important because despite its administration 
being increasingly common practice worldwide,27 our study 
demonstrates limited available evidence for its use.
According to our analysis, in terms of efficacy, the admin-
istration of nebulized antibiotics might increase the likeli-
hood of clinical resolution (particularly in VAP caused by 
resistant pathogens), but this is not consistently translated 
into a significant improvement in mortality or mechanical 
ventilation duration. Antibiotic nebulization also appears 
to have a protective effect against the emergence of resistant 
strains when used for the treatment of VAT or even VAP 
caused by susceptible pathogens. This contrasts with previ-
ous studies, reported before 1985,1–6 probably due to techni-
cal limitations in the delivery of the drug and the prolonged 
administration periods at that time. In terms of safety, our 
Table 3. Main Characteristics and Administration Strategy of the Included Studies
Study and Year Country Characteristics





  Palmer et al. 
200834
USA Phase III study, double-blinded, 
placebo-controlled, single center
43 VAT, mixed  
susceptibility
Jet nebulizer  
  Palmer and  
Smaldone 
201435
USA Phase III study, double-blinded, 
placebo-controlled, single center
47 VAT, mixed  
susceptibility
Jet nebulizer  





Phase II study, double-blinded,  
placebo-controlled, parallel 
group, multicentric
67 VAP, resistant 
pathogens
Vibrating-mesh  





  Lu et al.  
201126






  Hallal et al.  
200741
USA Phase III study, double-blinded, 
pilot study, single center
10 VAP† Jet nebulizer Substitution 
strategy*
  Rattanaumpawan 
et al. 201042
Thailand Phase III study, open label, single 
center





  Ghannam et al. 
200940
USA Matched case–control study,  
retrospective, single center
32 VAP, resistant 
pathogens
Jet nebulizer Substitution 
strategy
  Kofteridis et al. 
201037
Greece Matched case–control study (ratio 
1:1), retrospective, single center








  Doshi et al.  
201338
USA Cohort analysis, retrospective, 
multicentric
95 VAP, resistant 
pathogens
Jet nebulizer (in two  
centers), vibrating- 




  Tumbarello et al. 
201339
Italy Matched case–control study (ratio 
1:1), retrospective, single center
208 VAP, resistant 
pathogens





  Arnold et al. 
201243
USA Cohort study, retrospective, single 
center
90 VAP† Not defined but they 
specified using a  
nebulizer generating 




*Studies included only in the evaluation of adverse effects. †The susceptibility pattern of the pathogens is not specified as they are not relevant for the 
analysis of their adverse effects.
PDDS = pulmonary drug delivery system; VAP = ventilator-associated pneumonia; VAT = ventilator-associated tracheobronchitis.
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analysis reveals that the risk of nephrotoxicity might be lower 
when the antibiotics are nebulized instead of administered 
IV. In July 2016, a new systematic search of the literature was 
performed, identifying one new RCT by Abdellatif et al.,44 
performing colistin nebulization under a strategy equivalent 
to the substitution strategy. Due to limitations in its design, it 
did not meet our eligibility criteria for its efficacy evaluation, 
but we evaluated their data regarding safety (nephrotoxicity), 
which was consistent with the results of our analysis (fig. 7B), 
suggesting less occurrence of nephrotoxicity when nebulized 
antibiotics are administered (for both RCT included: Risk 
difference, −0.23; 95% CI, −0.37 to −0.10; I2 = 0%; for 
pooled analysis of all: Risk difference, −0.25; 95% CI, −0.37 
to −0.14). Finally, our study also reveals a 9% increase in risk 
of respiratory complications, especially when they are admin-
istered to severely hypoxemic patients, such as severe acute 
respiratory distress syndrome patients.
The main limitations of our study are its small sample size 
and the fact that only half of the included studies were RCTs. 
Due to the small sample size of the studies, no subgroup analyses 
could be performed, such as a comparison of the efficacy among 
the three different types of devices used or between the differ-
ent drugs administered. As the number of RCTs included in the 
meta-analysis was also very small, a meta-regression could not be 
performed. Two of the RCTs were not blinded and for the analy-
sis of one of the PICO questions (regarding treatment of VAT), 
all the included studies were from the same investigator, which 
introduces a possibility of bias on the results of that specific anal-
ysis. However, this is not only a limitation, but an interesting 
denouement, as it evidences the lack of RCTs in this field.32,45
Another limitation is the fact that all of the included 
studies in our meta-analysis were published between 2007 
and 2015. Clinical studies published before 2014 may have 
used infratherapeutic doses of the drugs, as the recom-
mended doses of colistin and aminoglycosides have mark-
edly increased the last years based on pharmacokinetics/
pharmacodynamics studies.23,46,47 Also, continuous renal 
replacement therapy might be a confounder, requiring a sub-
stantial modification in the administered doses.48,49
It is also likely that some overlap is present between VAT 
and VAP in the analyzed studies, given the difficulty in their 
diagnosis.50 Moreover, for the analysis of one PICO question 
(regarding VAT), the Clinical Pulmonary Infection Score used 
as an outcome for clinical resolution in the included studies was 
not a predefined outcome of our analysis. However, as the PaO2/
FIO2 is a predictor of mortality and clinical resolution in VAP,
51 
and as both entities—VAP and VAT—are closely linked and 
overlapping, we considered that a decrease in Clinical Pulmo-
nary Infection Score in patients treated for VAT was fulfilling 
the third criteria of our predefined terms of clinical resolution 
(table 2) and included these studies in the analysis. Another 
limitation was that some of the outcomes were surrogated, and 
some of the included studies had heterogeneous populations, 
with potentially higher risk of mortality and/or morbidities 
than the average population included (e.g., oncologic patients, 
delayed targeted antibiotic therapy). Finally, our study protocol 
was not previously published or registered in a platform like 
PROSPERO (International Prospective Register of Systematic 
Fig. 3. Emergence of resistant strains in patients treated with nebulized antibiotics for ventilator-associated tracheobronchitis. 
I = heterogeneity index; M–H = Mantel–Haenszel.
Fig. 2. Risk of bias summary for the randomized clinical trials.
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Reviews, https://www.crd.york.ac.uk/PROSPERO/). However, 
all clinically relevant questions were identified and defined a pri-
ori, using the PICO format, and the initial protocol was never 
modified. Meta-analyses may result in type I errors owing to an 
increase of random error when sparse data are analyzed.52
The main strength of our meta-analysis is our strict inclu-
sion of studies. The nebulization devices used in the included 
studies were restricted to the ones providing sufficiently small 
particles to reach the lung parenchyma (jet, ultrasonic, and 
vibrating-mesh nebulizers). Similarly, the population of the 
included studies was also strictly selected (e.g., only studies 
involving invasively mechanically ventilated patients were 
included, studies with colonized-but-not-infected patients 
were also excluded). Our strict selection limited the study size 
as a drawback, but also makes our results more robust and 
generalizable to the study population, in contrast with pre-
vious reviews53–57 that had highly heterogeneous results and 
a potential overestimation of the effects. This is the reason 
why VAT and VAP were analyzed separately, contrasting with 
recent systematic review and meta-analysis.53–57 Our study 
is also the first to analyze different administration strategies 
(adjunctive and substitution) separately. Finally, our analysis 
adds value regarding important information on safety aspects 
such as respiratory or nephrotoxicity adverse events.
In conclusion, our study shows that very limited evidence 
exists on the use of nebulized antibiotics in mechanically 
ventilated patients. Improvement in clinical resolution does 
not translate to improvements in other significant outcomes, 
which should be enclosed in further studies as predetermined 
outcomes. Patients with resistant pathogen-related infections 
might potentially derive greater benefit from nebulized anti-
biotic therapy. Its use, without the concomitant IV admin-
istration of the drug, may reduce nephrotoxicity associated 
with systemic colistin or aminoglycosides. Administration of 
Fig. 4. Clinical resolution of patients treated with nebulized antibiotics for ventilator-associated tracheobronchitis caused by 
resistant pathogens—adjunctive administration strategy. I = heterogeneity index; M–H = Mantel–Haenszel; RCT = randomized 
controlled trial.
Fig. 5. Mortality of patients treated with nebulized antibiotics for ventilator-associated pneumonia (VAP) caused by resistant 
pathogens—adjunctive administration strategy. I = heterogeneity index; M–H = Mantel–Haenszel.
Downloaded from anesthesiology.pubs.asahq.org by guest on 01/13/2020
Copyright © 2017, the American Society of Anesthesiologists, Inc. Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Anesthesiology 2017; 126:890-908 898 Solé-Lleonart et al.
Aerosolized Antibiotics
nebulized antibiotics seems to be associated with a higher 
risk of respiratory complications, particularly in severely 
hypoxemic patients. Therefore, future studies should stratify 
patients based on the degree of hypoxemia. Our findings evi-
dence that in an era of emerging Gram-negative–resistant 
organisms, further research with larger RCT including more 
homogeneous populations, standardized drug delivery, and 
clinically relevant predetermined outcomes is an urgent and 
unmet clinical need.
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Appendix 1: list of Terms of the Search 
Strategy
#1 “Aerosols” [Mesh]







#9 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8








#18 #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 
OR #17
#19 “Pneumonia, Ventilator-Associated” [Mesh]






#26 ventilator associated tracheobronchitis*[tiab]
#27 vat[tiab]
#28 viral respiratory infection*[tiab]




#33 #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR 
#26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32






















#56 #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 
OR #42 OR #43 OR #44 OR #45 OR #46 OR #47 OR 
#48 OR #49 OR #50 OR #51 OR #52 OR #53 OR #54 
OR #55
#57 #18 OR #56
#58 #9 AND #33 AND #57
#59 #34 OR #58
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Appendix 2: Appendix to “Materials and 
Methods”
Eligibility Criteria
Randomized controlled trials, observational studies, and case series 
evaluating efficacy and/or safety of nebulized antiinfective agents for 
the treatment of respiratory infections in invasively mechanically ven-
tilated adult patients were eligible if the delivery of the drug was per-
formed with devices generating particles smaller than 5 μm of diameter: 
jet nebulizers, ultrasonic nebulizers, or vibrating-mesh nebulizers.
Exclusion criteria included studies involving pediatric patients, 
patients without invasive mechanical ventilation support, patients 
diagnosed as being colonized but not infected, and patients with 
particular characteristics such as burn-injured patients or patients 
receiving support with renal replacement therapies and/or cardio-
pulmonary support with extracorporeal life support devices such as 
extracorporeal membrane oxygenation, due to the lack of knowl-
edge on the impact these techniques might have in the technique 
being evaluated. Studies involving patients with cystic fibrosis or 
other non-cystic fibrosis were also excluded as they were considered 
to have particular characteristics deserving a separate evaluation. 
Studies reporting delivery with other devices, or other practices 
such as tracheal instillation (either manually or with a pneumatic 
pump), were rejected as they produce larger particles that may not 
sufficiently reach the lung parenchyma.
A list of efficacy and safety outcomes to be evaluated (table 2) 
was independently rated by all authors according to their potential 
clinical relevance or impact on answering the Population-Interven-
tion-Comparison-Outcome questions. Outcomes were classified as 
being “nonimportant” (rated 1 to 3), “important” (4 to 6), or “criti-
cal” (7 to 9). Only critical outcomes (with a mean score equal to or 
more than 7) will be evaluated under the Grading of Recommenda-
tions Assessment, Development and Evaluation methodology.
Study Selection 
Three authors (S.B., G.P., and C.S.-L.) independently assessed all 
the studies identified in the literature search by screening their titles 
and abstracts. Disagreements between reviewers were resolved by 
consensus. In case of disagreement, a fourth independent reviewer 
(I.S.) determined the eligibility. Authors of articles considered for 
rejection due to lack of information (e.g., type of device used) were 
contacted to provide further details.
Data Collection Process
Full texts of the selected studies were obtained. A data sheet, based 
on the recommendations of the Cochrane Handbook for System-
atic Reviews of Interventions,23 was developed for data extrac-
tion, which was performed by one author (C.S.-L.) and afterward 
checked by a second independent reviewer (S.P.). Authors of arti-
cles with relevant nonreported or unclear data were contacted to 
provide further information.
Data Items 
For each included study, the following data were extracted: gen-
eral information regarding the study design, inclusion/exclusion 
criteria, etc.; type of intervention performed (including the type of 
device for delivery); main and secondary outcomes evaluated and 
adverse events reported.
Risk of Bias Assessment
Risk of bias was assessed for every included study by one author 
(C.S.-L.) and afterward checked by a second independent 
reviewer (S.P.) from the Iberoamerican Cochrane Center, Bar-
celona, Spain. Assessment was performed based on the recom-
mendations of the Cochrane Handbook for Systematic Reviews 
of Interventions31: bias regarding selection, performance, detec-
tion, attrition, and reporting was assessed for all randomized 
controlled trials. Bias risk was also assessed for observational 
studies under the recommendations of the Cochrane Handbook 
for Systematic Reviews of Interventions,31 evaluating selection 
and representativity of the cohorts, presence of confounding 
factors, and adequacy of both the outcomes and their following 
process.
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Table A3.2. Studies Regarding the Use of Nebulized Antibiotics for the Treatment of VAT: Evaluated Outcomes and Quality
Study and Year Efficacy Outcomes Safety Outcomes Global Bias Risk Particularities
Randomized controlled trials
  Palmer et al.  
200834
Clinical resolution (reduction in  
CDC-NNIS and CPIS scores)
Secondary:
 Leukocyte count (day 14)
 Systemic antibiotic use
 Weaning from MV
 Mortality
 Emergence of new resistant strains
  Bacterial growth in semiquantitative 
tracheal aspirate cultures
None evaluated Low risk of bias Most patients had criteria for VAP 
diagnose at randomization (five in 
the group receiving NA; six in the 
group not receiving local therapy). 
Authors were contacted to clarify 
this particularity. They considered 
to be treating only VAT due to the 
characteristics of the device used 
for nebulization




 Eradication of MDRO
Secondary:
 Emergence of new resistant strains
Clinical resolution (CPIS score, 
leukocyte count, fever, volume of 
secretions, etc.)
 Duration of MV
  Mortality
Nephrotoxicity Low risk of bias 
(uncertain risk 
on losts in the 
monitoring: five 
patients in the 
placebo group 
were removed 
from the study 
by their fam-
ily or were 
transferred to 
another facility)
There can be a quantity of patients 
included in the NA group having 
criteria for a VAP diagnose, as 
initial APACHE score was sig-
nificantly higher in this group, in 
comparison to the APACHE score 
in the group receiving no local 
therapy. Authors were contacted 
to clarify this particularity. They 
considered to be treating only VAT 
due to the characteristics of the 
device used for nebulization
APACHE  =  Acute Physiology and Chronic Health Evaluation; CDC-NNIS  =  Centers for Disease Control-National Nosocomial Infections Surveillance; 
CPIS = Clinical Pulmonary Infections Score; MDRO = multiple drug-resistant organisms; MV = mechanical ventilation; NA = nebulized antibiotics; VAP = ven-
tilator-associated pneumonia; VAT = ventilator-associated tracheobronchitis.
Appendix 3: Main Characteristics and Quality of the Included Studies
Table A3.1. Studies Regarding the Use of Nebulized Antibiotics for the Treatment of Ventilator-associated Tracheobronchitis: Main 
Characteristics








Nebulized Drug  
and Dosage IV Drugs
Randomized controlled trials










43 patients  
(19 receiving 








120 mg/8 h;  
gentamycin:  
80 mg/8 h
According to clinician’s decision.
Targeted IV antibiotics at randomization: 
17 patients receiving NA (89.5%), 15 
patients not receiving local therapy 
(62.5%); no significant difference 
between both groups (P = 0.08)











47 patients  
(24 receiving 









120 mg/8 h; gen-
tamycin sulfate: 
80 mg/8 h; amika-
cin: 400 mg/8 h
According to clinician’s decision.
Targeted IV antibiotics at randomiza-
tion: 16 patients receiving NA (66%), 
14 patients not receiving local therapy 
(77%); no significant difference between 
both groups (P = 0.51)
IV = intravenous; NA = nebulized antibiotics.
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Table A3.3. Studies Regarding the Use of NA for the Treatment of Ventilator-associated Pneumonia Caused by Resistant 
Pathogens: Main Characteristics
Study and  
Year Country Characteristic
No. of  
Patients
Type of  
Nebulizer
Nebulized Drug and 
Dosage IV Drugs
Randomized controlled trials
  Niederman  










phase II study, 
multicentric
67 patients  
(45 receiving 




nebulizer (PDDS  
Clinical®)






400 mg/12 h and 
400 mg/24 h
IV aminoglycosides could be 
administered
At day 1, the mean number of 
IV antibiotics per patient per 
day was 1.4 and 1.5 for the 
groups receiving NA and 1.6 
for patients not receiving 
local therapy. No significant 
difference was observed 
between the groups 
(P = 0.91)
Observational trials
  Ghannam  








32 patients Jet nebulizer Colistin or  
aminoglycosides
Dose: colistin: 
100 mg/8 h, 
tobramycin: 
30 mg/12 h,  
amikacin: 
100 mg/8 h, and 
gentamicin: 
100 mg/8 h
IV colistin or aminoglycosides.
All patients in both groups 
received other concomitant 
IV antibiotics (detailed in 
table 2 of the study). Both 
groups had also a similar 
duration of antibiotherapy: 
11 days in the NA group 
(with a range from 3 to 26) 
and 10 days in the IV group 
(range from 2 to 21 days), 
P > 0.8
  Kofteridis  
et al.  
201037
Greece Matched case– 
control study 
(ratio 1:1),  
retrospective, 
single center






Dose: two MIU per 
day, divided into 
two doses
All patients received IV colistin 
(both cases and controls).
Dose: nine MIU per day, 
divided in three doses
No references to other IV anti-
biotics being administered
  Doshi  







95 patients Jet nebulizer (in 
two centers), 
vibrating-mesh 
nebulizer (in one 
center)
Colistin
Two different doses: 
75 mg/12 h (in 
two centers) and 
150 mg/12 h (in 
one center, via jet)
All patients received IV colistin 
(both cohorts).
Doses detailed in table 1 of 
the study. Globally, if CrCl 
> 80 ml/min, two centers 
administered 5 mg ∙ kg−1 ∙ 
day−1 of colistin (divided in 
two doses). The other center 
administered the same dose 
if CrCl > 70 ml/min.
Additional IV antibiotics 
administered in 43.2% of 
patients receiving adjunctive 
NA and in 64.7% of patients 
receiving IV therapy alone (P 
= 0.036)
  Tumbarello  
et al.  
201339
Italy Matched case– 
control study 
(ratio 1:1),  
retrospective, 
single center




Dose: three MIU 
per day divided in 
three doses
All patients received IV colistin 
(both cases and controls)
Dose: 100.000 IU ∙ kg−1 ∙ 
day−1, every 8 to 12 h
No references to other IV 
antibiotics being adminis-
tered (but their patients were 
infected by colistin-only–
susceptible pathogens)
CMS = colistimethate sodium; CrCl = creatinine clearance; IU = international units; IV = intravenous; MIU = millions of international units; NA = nebulized 
antibiotics; PDDS = Pulmonary Drug Delivery System.
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Table A3.4. Studies Regarding the Use of NA for the Treatment of VAP Caused by Resistant Pathogens: Evaluated Outcomes and 
Quality




  Niederman  
et al. 201236
Primary:
 PK/PD analysis in the tracheal aspi-
rates
Secondary:
 Clinical resolution (complete/ 
partial resolution of pneumonia 
signs and symptoms, improvement/
lack of progression of all abnormali-
ties on chest x-ray and no additional 
IV antibiotics since completion of 
study treatment)
 Microbiologic eradication




Low risk of 
bias
Inclusion of patients with HCAP
Secondary outcomes were evalu-
ated in the efficacy population 
(completing ≥ 7 days of study 
drug/placebo: 16 patients in each 
group, 48 patients in total)
Adverse events were evaluated in 
the safety population (patients who 
had been screened, randomized, 
and had received at least one 
dose of treatment, a total of 67 
patients: 45 patients receiving NA 
and 22 in placebo group)
Observational trials
  Ghannam  
et al.40
Primary:
 Clinical resolution of VAP  
(improvement of clinical  
parameters, ventilator parameters, 
laboratory findings and/or reced-
ing pulmonary infiltrates on a chest 
x-ray at the end of therapy)
Secondary:
 Bacterial eradication.





Low risk of 
bias
The population of the study is onco-
logic patients. Therefore, this is a 
selected population with prob-
ably higher risk of mortality and 
morbidities
All patients received prophylaxis 
with β-agonist bronchodilators 
before and after the aerosolization. 
Therefore, this study was excluded 
for the analysis of this particular 
outcome
  Kofteridis  
et al. 201037
Primary:
 Clinical resolution of VAP  
(resolution of signs and symptoms 











Low risk of 
bias
 
  Doshi 
 et al. 201338
Primary:
 Clinical resolution of VAP  
(resolution of signs and symptoms 




 Duration of MV
 Duration of ICU stay
  Microbiologic cure
None Low risk of 
bias
Not all the included patients were 
MV: a 4.5% in the adjunctive 
therapy with NA and a 3.9% in the 
systemic therapy alone, were not 
under MV
Even though, as the MV patients 
were more than 95% in both 
groups, and there was no sta-
tistically significant difference 
between them due to this factor 
(P > 0.999), the experts committee 
decided not to exclude this article
  Tumbarello  
et al. 201339
Primary:
 Clinical resolution of VAP  
(resolution of signs and symptoms 
of infection and improvement/lack of 
progression of chest x-ray abnor-
malities by the end of the treatment)
Secondary:
 Mortality
 Duration of MV
 Duration of ICU stay
  Microbiologic cure
Nephrotoxicity Low risk of 
bias
 
HCAP = healthcare-associated pneumonia; ICU = intensive care unit; IV = intravenous; MV = mechanical ventilation; NA = nebulized antibiotics; PD = 
pharmacodynamics; PK = pharmacokinetics; VAP = ventilator-associated pneumonia.
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Table A3.6. Studies Regarding the Use of Nebulized Antibiotics for the Treatment of VAP Caused by Susceptible Pathogens: 
Evaluated Outcomes and Quality
Study and Year Efficacy Outcomes
Safety  
Outcomes Global Bias Risk Particularities
Randomized controlled trials
  Lu et al.  
201126
Primary: 
 Clinical and bacteriologic cure 
of VAP after 8 complete days 
of antibiotic therapy (associa-
tion of reduction of clinical 
and biologic signs of infec-
tion, decrease in the modified 
CPIS score < 6, significant 
lung CT improvement, and 
lower respiratory tract speci-




 Antibiotic-induced changes in 
lung aeration and lung-inflam-
mation (assessed by CT scan)




Low risk of bias except for 
a high risk of bias in the 
blinding (a nonblinded 
investigator evaluated 
curation and possibility 
of superinfection after the 
treatment)
The majority of the global 
selected population in the 
study had an inadequate 
initial antibiotic treat-
ment. Therefore, this is a 
selected population that 
may have a higher risk of 
mortality and morbidities
CPIS = Clinical Pulmonary Infection Score; CT = computed tomography; VAP = ventilator-associated pneumonia.
Table A3.5. Studies Regarding the Use of Nebulized Antibiotics for the Treatment of Ventilator-associated Pneumonia Caused by 
Susceptible Pathogens: Main Characteristics
Study and 
Year Country Characteristic
No. of  
Patients
Type of  
Nebulizer
Nebulized Drug 
and Dosage IV Drugs
Randomized controlled trials
  Lu et al. 
201126
France Phase II trial, 
single center





25 mg kg−1 
day−1; single 
dose; duration: 3 
days. ceftazi-
dime: 120 mg 
kg−1 day−1; 
divided in 8 
doses of 15 mg/ 
kg each; dura-
tion: 8 days
IV amikacin plus ceftazidime
Amikacin: 15 mg ∙ kg−1 ∙ day−1; 
single dose; duration: 3 days. 
Ceftazidime: initial bolus of 
30 mg/kg more than 30 min plus 
continuous infusion of 90 mg ∙ 
kg−1 ∙ day−1; duration: 8 days
Patients infected with Pseu-
domonas aeruginosa with an 
intermediate susceptibility to 
ceftazidime and/or amikacin  
(3 patients out of 20), were 
treated in with ciprofloxacin
IV = intravenous.
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Table A3.7. Studies Regarding the Use of NA for the Treatment of Ventilator-associated Pneumonia Independently of the Pathogen’s 
Susceptibility Pattern: Main Characteristics
Study and Year Country Characteristic
No. of  
Patients
Type of  
Nebulizer
Nebulized Drug and 
Dosage IV Drugs
Randomized controlled trials





10 patients Jet nebulizer Tobramycin
Dose: 300 mg/12 h
IV tobramycin on a single 
daily dose, adjusted 
according to the renal 
function (creatinine 
clearance)
Patients in both groups 
could also receive 





tion was provided on 
potential significantly 
different distribution 
of these antibiotics 
between both groups
  Rattanaumpawan 
et al. 201042
Thailand Open label,  
single center
102 patients Jet and ultrasonic 
nebulizers
CMS
Dose equivalent to 
75 mg of colistin 
base, every 12 h
Regimen and duration of 
IV antibiotics decided 
by the patient’s 
responsible physician
Table 1 in the study 
shows no significant 
differences in the dis-
tribution of the different 
types of antibiotics 
between both groups
Observational trials





90 patients Not defined but 
they specified 
















or amikacin (4 of 
20 patients) were 
treated with both 
nebulized ceftazi-
dime and amikacin
Regimen and duration of 
IV antibiotics decided 
by the patient’s 
responsible physician
Significantly higher 
rate of IV colistin and 
aminoglycosides in 
the group receiving 
adjunctive NA
CMS = colistimethate sodium; IV = intravenous; NA = nebulized antibiotics.
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Table A3.8. Studies Regarding the Use of NA for the Treatment of VAP Independently of the Pathogen’s Susceptibility Pattern: 
Evaluated Outcomes and Quality
Study and Year Efficacy Outcomes Safety Outcomes Global Bias Risk Particularities
Randomized controlled trials
  Hallal et al.  
200741
Primary:
 Resolution of VAP (extu-
bation within the study 
period/still MV but with 
improval of Multiple Organ 
Dysfunction Scores, fever, 
pulmonary infiltrates and 
physical signs of pneumo-
nia resolved).
Secondary:
 Superinfection by Pseu-
domonas aeruginosa or 
Acinetobacter spp.
 Bacteremia by P. aeruginosa 
or Acinetobacter spp.
  Need to change the therapy 
regimen
Systemic toxicity  
(nephrotoxicity)




not provided (a potential 
significantly different 
distribution may exist 
between both groups) 
the experts committee 
decided to exclude this 
study for efficacy evalua-
tion. It was only included 
for safety evaluation
  Rattanaumpawan  
et al. 201042
Primary:
 Clinical resolution (complete 
resolution of all signs and 
symptoms of VAP, and 
improvement/lack of pro-
gression of all abnormali-
ties on the chest x-ray
 Microbiologic outcome  
(days 3 and 7).





High risk of bias of blinding 
(open label)
Low risk of bias in the rest of 
the evaluation
They mixed both MDRO 
pathogens and suscep-
tible microorganisms. 
Prevalence of MDRO was 
58.8% in the adjunctive 
nebulized therapy group 
and 40.8% in the placebo 
group (P = 0.11)
Observational trials
  Arnold et al.  
201243
Mortality (30 days and  
in-hospital)
Duration of MV
Duration of ICU stay
Length of IV therapy
Recurrence of VAP
They report no 
adverse effects 









Low risk of bias except for 
a high risk of bias for 
confounding factors; the 
group receiving adjunctive 
NA had significantly higher 
rate of MDRO pathogens 
(P < 0.001), significantly 
higher APACHE II score 
(P = 0.004), significantly 
higher rate IV aminogly-
cosides (P = 0.001), and 
significantly higher rate of 
IV colistin (P = 0.02)
Risk of overestimation of 
nephrotoxicity and respir-
atory complications in the 
group receiving adjunctive 
NA due to the confound-
ing factors previously 
described in the table
APACHE = Acute Physiology and Chronic Health Evaluation; ICU = intensive care unit; IV = intravenous; MDRO = multiple drug-resistant organisms; MV = 
mechanical ventilation; NA = nebulized antibiotics; spp. = species; VAP = ventilator-associated pneumonia. 
Appendix 4: Study Characteristics and 
Meta-analysis on efficacy and Safety of 
Nebulized Antivirals for the Treatment of 
Viral Infections 
No randomized trials or observational studies were found to evalu-
ate the efficacy and/or safety of nebulized antivirals for the treat-
ment of viral infections; therefore, no evidence can be provided on 
their use. Only some case series and reports on nebulization of zana-
mivir were found.58 Zanamivir is not approved for nebulization, 
and the Food and Drugs Administration alerted in October 2009 
(http://www.medscape.com/viewarticle/710336) of the death of a 
person with influenza who had received its powder for inhalation 
formulation through a nebulizer. According to the manufacturer, 
lactose sugar in the formulation increases the risk of obstruction of 
the mechanical ventilator circuit.
Appendix 5: Study Characteristics and 
Meta-analysis on efficacy and Safety of 
Nebulized Antifungals for the Treatment of 
Fungal Infections
No randomized controlled trials or observational studies were found 
to evaluate the efficacy and/or safety of nebulized antifungals for 
the treatment of fungal infections. Only one case series59 reported 
their experience on nebulization of Amphotericin B Lipid Complex 
(Sigma Tau Pharmaceuticals, USA) to 32 immunosuppressed oncol-
ogy patients as adjunctive therapy to systemic antifungals. Only eight 
patients were under mechanical ventilation support and had a dem-
onstrated fungal infection. Only one of the patients was reported to 
have survived. They also reported respiratory complications (modest 
cough, mild bronchospasm, and transient chest pain) in three patients 
although it was not specified if those patients were under mechanical 
ventilation or not. No other evidence was found for the use of nebu-
lized antifungals for the treatment of fungal respiratory infections.
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